Orbis Allan Gray LTD Alnylam Pharmaceuticals, Inc. Transaction History
Orbis Allan Gray LTD
- $15.3 Billion
- Q2 2025
A detailed history of Orbis Allan Gray LTD transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Orbis Allan Gray LTD holds 2,121,412 shares of ALNY stock, worth $912 Million. This represents 4.54% of its overall portfolio holdings.
Number of Shares
2,121,412
Previous 1,634,923
29.76%
Holding current value
$912 Million
Previous $441 Million
56.7%
% of portfolio
4.54%
Previous 3.18%
Shares
6 transactions
Others Institutions Holding ALNY
# of Institutions
742Shares Held
115MCall Options Held
584KPut Options Held
672K-
Capital World Investors Los Angeles, CA16.8MShares$7.22 Billion0.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$5.72 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.1 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.19MShares$3.09 Billion0.49% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.28MShares$1.84 Billion0.88% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $52.9B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...